GHP Q2 2022

59 GHP Q2 2022 As one of the world’s most recognised clinical research organisations, MMS Holdings has come a longway since its creation in themid-2000s.As theBest Data-FocusedPharmaceutical Clinical Research Organization, 2022 – USA, the organisation offers premium, flexible, and professional services to clients around the globe. Supporting Projects with Advanced Data MS Holdings is a leading data-focused clinical research organisation that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Founded in 2006 by Dr. Uma Sharma, MMS Holdings began with the goal to transform a one-person consultancy into an internationally esteemed clinical research organisation. In 2022, it is safe to say that the organisation has hit – and exceeded – this target. Indeed, MMS Holdings maintains over 800 team members worldwide, and is continuing to grow. Henceforth, it is imperative that MMS Holdings possesses a shared mission throughout its international workforce. The organisation strives to provide value that exceeds its competition. Simply, its mission encompasses client-centricity, involving the delivery of high-quality services and premium technology solutions. Each solution must be anchored in science and supported by the company’s decades of shared regulatory experience and must contribute to the success of its clients’ projects. By following this mission, MMS Holdings has contributed to 50 submissions for drug approval with the FDA and other global health authorities over the past five years whilst maintaining a 97% customer satisfaction rate. Much of this stems from the organisation’s treatment of its clients, as it focuses on the client and their goals throughout the lifecycle of the project. Moreover, the company’s client-centric nature ensures that it not only pleases customers, but also retains them. One of the testimonials featured on its website reads as follows: ‘MMS is the only company I would reach out to, big or small. MMS understood and worked within our capabilities and with our unconventional strategies we were forced into by the nature of being small and underfunded. Your team worked with us, diligently, beyond expectations, and got us over the finish line to success.’ As stated within the review, the team plays a significant role in the company’s growth – without them, the team would not have been able to acquire an international level of prestige. MMS Holdings promotes a Sense of Urgency and Leadership (SOUL) through a healthy work environment, resulting in this being a shared attitude amongst the staff. Colleagues keep the big picture in mind and understand that each clinical trial, dataset, or report that they deliver fits in the context of a larger development program and set of organizational goals. Additionally, the staff satisfaction is clear. MMS Holdings has some of the lowest employee attrition rates in the industry at 3.5% per annum. Throughout the peak of the Covid-19 pandemic, MMS Holdings was able to retain staff and even created a $1,000,000 grant to eliminate the financial burden of creating a vaccine or other therapy for COVID-19. The award was offered to qualifying companies who were supporting the commercial development of a vaccine for approval in the United States or other international health authorities and came in the form of data and related services. MMS Holdings’ portfolio also grew to include Covid-19 related vaccines and drugs on top of existing projects and clients. This came alongside the challenge of having an entirely remote workforce and the need to learn and implement methodologies that existed prior as only a reference, such as Emergency Use Authorization (EUA.) In addition, MMS joined the historic Decentralized Trials & Research Alliance (DTRA) in 2020 as a Founding Member – an alliance that has grown to over one hundred life sciences and healthcare organisation that seeks to accelerate the adoption of decentralised clinical trials and research. Going forward, MMS Holdings will continue to focus on innovation, creating effective solutions for each of its clients. In 2022, this will be bolstered by its recently announced partnerships with Medidata and Thread Research. On top of this, the organisation will be increasing its Functional Service Provider (FSP) offerings. Such services allow for the hiring, training, and provision of support to employees who are dedicated to a specific sponsor. Contact: Olivia Grant Company: MMS Holdings Web Address: M Mar22766 “MMS Holdings is a leading data-focused clinical research organisation that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges.”